- A +

Management

Bernard Gilly, PhD

Bernard Gilly, PhD
Co-Founder, Chief Executive Officer

Bernard Gilly, PhD
Co-Founder, Chief Executive Officer

Bernard Gilly, PhD

Bernard Gilly is one of our founders, and has served as our Chief Executive Officer since GenSight's creation in 2012. 

Bernard has over twenty years of experience in the financial and pharmaceutical sectors. He co-founded several high potential start-ups, developing disruptive technologies in the biotech and medtech fields. He is currently non-executive Chairman of Pixium Vision (2011), EyeTechCare (2012), Gecko Biomedical (2013) and Chronocam (2015). From 2005 to 2009, he founded and was Chairman and Chief Executive Officer of Fovea Pharmaceuticals, a privately owned biotech company, which was acquired by Sanofi in 2009. After the acquisition, he became Senior Vice-President of the Ophthalmology Division of Sanofi until 2012.

Prior to Fovea, Dr. Gilly was a partner at Sofinnova Partners from 2000 to 2005. From 1992 to 2000, he was Chief Executive Officer of Transgene. At that time, he took the company public on the NASDAQ and the Nouveau Marché in France, raising over $120M in 1998. Prior to that, he was VP of R&D at Pasteur Mérieux Connaught (now Sanofi Pasteur).

Dr. Gilly received an engineering degree from Ecole Nationale d’Agronomie and a Ph.D. from Université de Rennes. 

Thomas Gidoin

Thomas Gidoin
Chief Financial Officer

Thomas Gidoin
Chief Financial Officer

Thomas Gidoin

From 2012 to mid-2015, Mr. Gidoin was Vice President Finance at DBV Technologies S.A., where he led the Corporate Finance team and participated in public offerings and private placements, including the dual listing of DBV Technologies S.A. on the NASDAQ Global Select Market in 2014.

From 2008 to 2011, Mr. Gidoin served at various positions at Ipsen S.A., including UK Operations Controller in London and Senior Financial Analyst in the Global Operations division in Paris.

He started his career in audit at Ernst & Young.

Mr. Gidoin received a Master’s degree in International Finance from ESGF Paris and a Master’s degree in International Management from Neoma Business School in France. 

Mohamed Genead, MD

Mohamed Genead, MD
Chief Medical Officer

Mohamed Genead, MD
Chief Medical Officer

Mohamed Genead, MD

Dr Genead is an Ophthalmologist, Medical retina specialist and a senior biopharmaceutical executive with more than 15 years of experience in Ophthalmology clinical research. He most recently served as Biogen Global Therapeutic Area Head of Ophthalmology and Retina Gene Therapy Areas where he led multiple gene-therapy programs in inherited retinal degenerative diseases.

Prior to joining Biogen, Mohamed was the Global Head of Clinical Development at Allegro Ophthalmic, where he led the global clinical development teams. Prior to this, Mohamed was Global project and clinical teams Lead for early proof of concept and late registration development programs in retina at Allergan, where he led projects as DARPins for wet AMD and DME and Brimonidine DDS implants for geographic atrophy. 

Before joining the industry, Mohamed spent years in academia serving as co-director of center for retina degenerative diseases, as an investigator and as clinician at University of Illinois in Chicago.  He is a member of numerous professional and honorary societies. He was the primary and key author for numerous key peer-reviewed manuscripts. Mohamed had his medical and fellowship training at Medical College of Wisconsin and the University of Illinois in Chicago.

Didier Pruneau, PhD

Didier Pruneau, PhD
Chief Scientific Officer

Didier Pruneau, PhD
Chief Scientific Officer

Didier Pruneau, PhD

Didier Pruneau, Ph.D., is our Chief Scientific Officer.

From 1983 to 2005, Dr. Pruneau was Head of the Department of Pharmacology at Fournier Pharma, then, from 2006 to 2009, he was Head of Scientific Operations at Fovea, and then from 2009 to 2013, Head of the Scientific Evaluation and Drug Discovery Ophthalmology Division at Sanofi.

Dr. Pruneau has expertise in pharmacology of G-protein coupled receptors, nuclear receptors and ion channels. Dr. Pruneau set up and led drug discovery programs in cardiovascular diseases, traumatic brain injury, skin diseases (wound healing), pain, metabolic diseases and ocular diseases, such as ARMD, diabetic retinopathy, glaucoma, ocular surface inflammatory diseases.

Dr. Pruneau received a Ph.D. in biochemistry from Dijon University and a master’s degree in pharmacology from Paris V University, followed by a fellowship in cardiovascular pharmacology in Melbourne, Australia.